These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12083002

  • 21. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination.
    Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, Chin C, Lin TH, Huang JH.
    Vaccine; 2001 Feb 08; 19(13-14):1753-63. PubMed ID: 11166901
    [Abstract] [Full Text] [Related]

  • 22. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
    Konishi E, Yamaoka M, Kurane I, Mason PW.
    Virology; 2000 Mar 01; 268(1):49-55. PubMed ID: 10683326
    [Abstract] [Full Text] [Related]

  • 23. Development of an effective Japanese encephalitis virus-specific DNA vaccine.
    Wu CJ, Li TL, Huang HW, Tao MH, Chan YL.
    Microbes Infect; 2006 Sep 01; 8(11):2578-86. PubMed ID: 16949850
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus.
    Okuno Y, Okamoto Y, Yamada A, Baba K, Yabuuchi H.
    Vaccine; 1987 Jun 01; 5(2):128-32. PubMed ID: 3037813
    [Abstract] [Full Text] [Related]

  • 26. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
    Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, Chang GJ.
    J Med Virol; 1994 Oct 01; 44(2):122-31. PubMed ID: 7852952
    [Abstract] [Full Text] [Related]

  • 27. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE.
    Vaccine; 2000 Oct 15; 19(4-5):483-91. PubMed ID: 11027812
    [Abstract] [Full Text] [Related]

  • 28. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y, Klade CS, Putnak R, Formica A, Krasaesub S, Spruth M, Cena B, Tungtaeng A, Gettayacamin M, Dewasthaly S.
    Vaccine; 2011 Aug 11; 29(35):5925-31. PubMed ID: 21723353
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Japanese encephalitis virus-specific proliferative responses of human peripheral blood T lymphocytes.
    Konishi E, Kurane I, Mason PW, Innis BL, Ennis FA.
    Am J Trop Med Hyg; 1995 Sep 11; 53(3):278-83. PubMed ID: 7573713
    [Abstract] [Full Text] [Related]

  • 31. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations.
    Konishi E, Suzuki T.
    Vaccine; 2002 Nov 22; 21(1-2):98-107. PubMed ID: 12443667
    [Abstract] [Full Text] [Related]

  • 32. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
    Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD.
    Vaccine; 2004 Sep 09; 22(27-28):3722-6. PubMed ID: 15315852
    [Abstract] [Full Text] [Related]

  • 33. A field trial of Japanese encephalitis vaccine produced in Thailand.
    Rojanasuphot S, Charoensuk O, Kitprayura D, Likityingvara C, Limpisthien S, Boonyindee S, Jivariyavej V, Ugchusak K.
    Southeast Asian J Trop Med Public Health; 1989 Dec 09; 20(4):653-4. PubMed ID: 2561722
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E, Ketloy C, Keelapang P, Sittisombut N, Ruxrungtham K.
    Asian Pac J Allergy Immunol; 2015 Sep 09; 33(3):182-8. PubMed ID: 26342114
    [Abstract] [Full Text] [Related]

  • 36. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L, Fu S, Gao X, Li M, Cui S, Li X, Cao Y, Lei W, Lu Z, He Y, Wang H, Yan J, Gao GF, Liang G.
    PLoS Negl Trop Dis; 2016 May 09; 10(5):e0004686. PubMed ID: 27139722
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G, Jian W, Feng X, Li-ping S, Quan-yun S, Jin-ping Z, Pu-yan C, Pei-hong L.
    Vaccine; 2008 Oct 16; 26(44):5590-4. PubMed ID: 18761388
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.